Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
314 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Fallopian Tube Cancer - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Fallopian Tube Cancer - Pipeline Review, H2 2014', provides an overview of the Fallopian Tube Cancer's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Fallopian Tube Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fallopian Tube Cancer and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Fallopian Tube Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Fallopian Tube Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Fallopian Tube Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Fallopian Tube Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Fallopian Tube Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Fallopian Tube Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Fallopian Tube Cancer Overview 9 Therapeutics Development 10 Pipeline Products for Fallopian Tube Cancer - Overview 10 Pipeline Products for Fallopian Tube Cancer - Comparative Analysis 11 Fallopian Tube Cancer - Therapeutics under Development by Companies 12 Fallopian Tube Cancer - Therapeutics under Investigation by Universities/Institutes 16 Fallopian Tube Cancer - Pipeline Products Glance 17 Late Stage Products 17 Clinical Stage Products 18 Fallopian Tube Cancer - Products under Development by Companies 19 Fallopian Tube Cancer - Products under Investigation by Universities/Institutes 22 Fallopian Tube Cancer - Companies Involved in Therapeutics Development 23 Johnson & Johnson 23 Boehringer Ingelheim GmbH 24 F. Hoffmann-La Roche Ltd. 25 Amgen Inc. 26 Eli Lilly and Company 27 GlaxoSmithKline plc 28 MedImmune, LLC 29 Daiichi Sankyo Company, Limited 30 Oxford BioMedica plc 31 Millennium Pharmaceuticals, Inc. 32 Novartis AG 33 Astellas Pharma Inc. 34 ImmunoGen, Inc. 35 Astex Pharmaceuticals, Inc. 36 CTI BioPharma Corp. 37 Bayer AG 38 Incyte Corporation 39 Active Biotech AB 40 Oncolytics Biotech Inc. 41 OXiGENE, Inc. 42 Curis, Inc. 43 Topotarget A/S 44 NeoStem, Inc. 45 Pharmacyclics, Inc. 46 Synta Pharmaceuticals Corp. 47 Oasmia Pharmaceutical AB 48 MabVax Therapeutics, Inc. 49 Acceleron Pharma, Inc. 50 Cerulean Pharma, Inc. 51 OncoMed Pharmaceuticals, Inc. 52 TetraLogic Pharmaceuticals 53 Merrimack Pharmaceuticals, Inc. 54 Immunovaccine, Inc. 55 Pharma Mar, S.A. 56 VentiRx Pharmaceuticals, Inc. 57 TRACON Pharmaceuticals, Inc. 58 Lee's Pharmaceutical Holdings Limited 59 Clovis Oncology, Inc. 60 Recepta Biopharma S.A. 61 EGEN, Inc. 62 Sanofi Pasteur SA 63 AbbVie Inc. 64 Fallopian Tube Cancer - Therapeutics Assessment 65 Assessment by Monotherapy Products 65 Assessment by Combination Products 66 Assessment by Target 67 Assessment by Mechanism of Action 71 Assessment by Route of Administration 75 Assessment by Molecule Type 77 Drug Profiles 79 pazopanib hydrochloride - Drug Profile 79 trebananib - Drug Profile 83 paclitaxel poliglumex - Drug Profile 86 paclitaxel - Drug Profile 90 binimetinib - Drug Profile 92 bevacizumab - Drug Profile 96 trabectedin - Drug Profile 101 rucaparib phosphate - Drug Profile 104 alisertib - Drug Profile 107 SGI-110 - Drug Profile 111 abiraterone acetate - Drug Profile 113 tasquinimod - Drug Profile 116 dalantercept - Drug Profile 118 elesclomol - Drug Profile 120 belinostat - Drug Profile 122 TroVax - Drug Profile 125 ramucirumab - Drug Profile 128 SG-2000 - Drug Profile 133 pelareorep - Drug Profile 135 nintedanib - Drug Profile 139 CRLX-101 - Drug Profile 142 VTX-2337 - Drug Profile 144 gimatecan - Drug Profile 146 seribantumab - Drug Profile 148 exatecan mesylate - Drug Profile 151 TRC-105 - Drug Profile 153 RebmAb-100 - Drug Profile 155 EGEN-001 - Drug Profile 157 NSC-748933 - Drug Profile 159 INCB-24360 - Drug Profile 160 birinapant - Drug Profile 162 Cancer Stem Cell Therapy - Drug Profile 164 DPX-Survivac - Drug Profile 165 linsitinib - Drug Profile 168 CDX-1401 - Drug Profile 170 ganetespib - Drug Profile 172 demcizumab - Drug Profile 176 fosbretabulin tromethamine - Drug Profile 179 BNC-105P - Drug Profile 183 Cell Therapy Targeting NY-ESO-1 and LAGE-1 for Cancer - Drug Profile 185 birinapant + conatumumab - Drug Profile 187 CUDC-427 - Drug Profile 189 abexinostat hydrochloride - Drug Profile 190 nintedanib - Drug Profile 192 vCP-2292 - Drug Profile 195 OC-DC Vaccine - Drug Profile 196 IMGN-853 - Drug Profile 197 ABT-767 - Drug Profile 198 anetumab ravtansine - Drug Profile 199 Globo-H-GM2-sTn-TF-Tn-KLH Vaccine - Drug Profile 201 Fallopian Tube Cancer - Recent Pipeline Updates 202 Fallopian Tube Cancer - Dormant Projects 302 Fallopian Tube Cancer - Discontinued Products 303 Fallopian Tube Cancer - Product Development Milestones 304 Featured News & Press Releases 304 Appendix 310 Methodology 310 Coverage 310 Secondary Research 310 Primary Research 310 Expert Panel Validation 310 Contact Us 311 Disclaimer 311
List of Tables Number of Products under Development for Fallopian Tube Cancer, H2 2014 13 Number of Products under Development for Fallopian Tube Cancer - Comparative Analysis, H2 2014 14 Number of Products under Development by Companies, H2 2014 16 Number of Products under Development by Companies, H2 2014 (Contd..1) 17 Number of Products under Development by Companies, H2 2014 (Contd..2) 18 Number of Products under Investigation by Universities/Institutes, H2 2014 19 Comparative Analysis by Late Stage Development, H2 2014 20 Comparative Analysis by Clinical Stage Development, H2 2014 21 Products under Development by Companies, H2 2014 22 Products under Development by Companies, H2 2014 (Contd..1) 23 Products under Development by Companies, H2 2014 (Contd..2) 24 Products under Investigation by Universities/Institutes, H2 2014 25 Fallopian Tube Cancer - Pipeline by Johnson & Johnson, H2 2014 26 Fallopian Tube Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2014 27 Fallopian Tube Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 28 Fallopian Tube Cancer - Pipeline by Amgen Inc., H2 2014 29 Fallopian Tube Cancer - Pipeline by Eli Lilly and Company, H2 2014 30 Fallopian Tube Cancer - Pipeline by GlaxoSmithKline plc, H2 2014 31 Fallopian Tube Cancer - Pipeline by MedImmune, LLC, H2 2014 32 Fallopian Tube Cancer - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 33 Fallopian Tube Cancer - Pipeline by Oxford BioMedica plc, H2 2014 34 Fallopian Tube Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H2 2014 35 Fallopian Tube Cancer - Pipeline by Novartis AG, H2 2014 36 Fallopian Tube Cancer - Pipeline by Astellas Pharma Inc., H2 2014 37 Fallopian Tube Cancer - Pipeline by ImmunoGen, Inc., H2 2014 38 Fallopian Tube Cancer - Pipeline by Astex Pharmaceuticals, Inc., H2 2014 39 Fallopian Tube Cancer - Pipeline by CTI BioPharma Corp., H2 2014 40 Fallopian Tube Cancer - Pipeline by Bayer AG, H2 2014 41 Fallopian Tube Cancer - Pipeline by Incyte Corporation, H2 2014 42 Fallopian Tube Cancer - Pipeline by Active Biotech AB, H2 2014 43 Fallopian Tube Cancer - Pipeline by Oncolytics Biotech Inc., H2 2014 44 Fallopian Tube Cancer - Pipeline by OXiGENE, Inc., H2 2014 45 Fallopian Tube Cancer - Pipeline by Curis, Inc., H2 2014 46 Fallopian Tube Cancer - Pipeline by Topotarget A/S, H2 2014 47 Fallopian Tube Cancer - Pipeline by NeoStem, Inc., H2 2014 48 Fallopian Tube Cancer - Pipeline by Pharmacyclics, Inc., H2 2014 49 Fallopian Tube Cancer - Pipeline by Synta Pharmaceuticals Corp., H2 2014 50 Fallopian Tube Cancer - Pipeline by Oasmia Pharmaceutical AB, H2 2014 51 Fallopian Tube Cancer - Pipeline by MabVax Therapeutics, Inc., H2 2014 52 Fallopian Tube Cancer - Pipeline by Acceleron Pharma, Inc., H2 2014 53 Fallopian Tube Cancer - Pipeline by Cerulean Pharma, Inc., H2 2014 54 Fallopian Tube Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H2 2014 55 Fallopian Tube Cancer - Pipeline by TetraLogic Pharmaceuticals, H2 2014 56 Fallopian Tube Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2014 57 Fallopian Tube Cancer - Pipeline by Immunovaccine, Inc., H2 2014 58 Fallopian Tube Cancer - Pipeline by Pharma Mar, S.A., H2 2014 59 Fallopian Tube Cancer - Pipeline by VentiRx Pharmaceuticals, Inc., H2 2014 60 Fallopian Tube Cancer - Pipeline by TRACON Pharmaceuticals, Inc., H2 2014 61 Fallopian Tube Cancer - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2014 62 Fallopian Tube Cancer - Pipeline by Clovis Oncology, Inc., H2 2014 63 Fallopian Tube Cancer - Pipeline by Recepta Biopharma S.A., H2 2014 64 Fallopian Tube Cancer - Pipeline by EGEN, Inc., H2 2014 65 Fallopian Tube Cancer - Pipeline by Sanofi Pasteur SA, H2 2014 66 Fallopian Tube Cancer - Pipeline by AbbVie Inc., H2 2014 67 Assessment by Monotherapy Products, H2 2014 68 Assessment by Combination Products, H2 2014 69 Number of Products by Stage and Target, H2 2014 72 Number of Products by Stage and Mechanism of Action, H2 2014 76 Number of Products by Stage and Route of Administration, H2 2014 79 Number of Products by Stage and Molecule Type, H2 2014 81 Fallopian Tube Cancer Therapeutics - Recent Pipeline Updates, H2 2014 205 Fallopian Tube Cancer - Dormant Projects, H2 2014 305 Fallopian Tube Cancer - Discontinued Products, H2 2014 306
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.